Access to drugs: the case of Abbott in Thailand.
作者信息
Cawthorne Paul, Ford Nathan, Wilson David, Kijtiwatchakul Kannikar, Purahong Virat, Tianudom Nimit, Nacapew Supatra
出版信息
Lancet Infect Dis. 2007 Jun;7(6):373-4. doi: 10.1016/S1473-3099(07)70118-4.
Abstract
摘要
相似文献
1
Access to drugs: the case of Abbott in Thailand.
Lancet Infect Dis. 2007 Jun;7(6):373-4. doi: 10.1016/S1473-3099(07)70118-4.
2
Abbott expands low cost Kaletra.
AIDS Patient Care STDS. 2006 Oct;20(10):731-2.
3
Abbott agrees to expand access to Kaletra/Aluvia.
AIDS Patient Care STDS. 2007 May;21(5):366. doi: 10.1089/apc.2007.9980.
4
[When Doctors Without Borders writes to Miles White, chairman of Abbott Laboratories].
Rev Med Suisse. 2006 Mar 29;2(59):882.
5
Improving access to second-line antiretrovirals.
Lancet. 2007 Apr 21;369(9570):1320. doi: 10.1016/S0140-6736(07)60609-6.
6
Kaletra (ABT-378/r) approved.
AIDS Treat News. 2000 Sep 22(351):2-3.
7
Is India ready to lead the battle for fair access to medicines?
Lancet Oncol. 2013 May;14(6):437. doi: 10.1016/S1470-2045(13)70197-9.
8
Drug access. AHF chides Abbott for ban on HIV drugs to Thailand.
AIDS Policy Law. 2007 Apr 6;22(7):9.
9
Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.
HIV AIDS Policy Law Rev. 2008 Dec;13(2-3):80-1.
10
Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
J Law Med Ethics. 2009 Summer;37(2):222-39. doi: 10.1111/j.1748-720X.2009.00367.x.
Zotero 插件